Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
21 Setembro 2023 - 8:30AM
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage
immuno-oncology company focused on the discovery and development of
next-generation therapeutics for cancer patients, today will
present new preclinical data from SNS-101, a clinical-stage
conditionally active, human monoclonal antibody targeting the
immune checkpoint VISTA (V-domain Ig suppressor of T cell
activation), at the Seventh Annual CRI-ENCI-AACR International
Cancer Immunotherapy Conference: Translating Science into Survival,
held on September 20 – 23, 2023 in Milan, Italy.
“We believe these data further support the potential
best-in-class PK and safety profile of SNS-101 and its ability to
effectively target VISTA, a promising, but difficult-to-drug immune
checkpoint,” said Edward van der Horst, Ph.D., Chief Scientific
Officer of Sensei Biotherapeutics. “Restricting drug activity to
low pH conditions, such as those found in the acidic tumor
microenvironment, allowed us to safely dose SNS-101 in our
multi-dose NHP study at increasing levels while maintaining linear
elimination kinetics and displaying no target-mediated drug
disposition or adverse effects. Paired with new mechanistic data
showing SNS-101 can shift immunosuppressive macrophages towards an
anti-tumor phenotype, we believe SNS-101 could provide a
transformative treatment option for patients. We look forward to
sharing data from our ongoing clinical trial later this year.”
Presentation Highlights:
- SNS-101 displayed linear elimination kinetics and no
target-mediated drug disposition or adverse effects in a multi-dose
GLP toxicology study in cynomolgus monkeys evaluating SNS-101 doses
of 1, 10 and 100 mg/kg.
- In MC38 tumor-bearing mice, SNS-101 alone and in combination
with an anti-PD-1 antibody shifted the cytokine expression profile
of immunosuppressive myeloid cells in the tumor microenvironment to
an anti-tumor, M1 phenotype. The expression of anti-tumor cytokines
was correlated with a reduction in tumor size.
Sensei is evaluating SNS-101 in a Phase 1/2 clinical trial in
patients with advanced solid tumors, and expects to report initial
monotherapy pharmacokinetic and safety data by year-end 2023.
Topline monotherapy and initial combination data are anticipated in
2024.
The full poster is available for viewing on Sensei’s website and
will be on display at the conference during Poster Session A, being
held today, September 21, 2023, from 12:30 pm to 2:00 pm CET.
About Sensei Biotherapeutics: Sensei
Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology
company focused on the discovery and development of next-generation
therapeutics for cancer patients. Through its TMAb™ (Tumor
Microenvironment Activated biologics) platform, Sensei develops
conditionally active therapeutics designed to disable
immunosuppressive signals or activate immunostimulatory signals
selectively in the tumor microenvironment to unleash T cells
against tumors. Sensei’s lead investigational candidate is SNS-101,
a conditionally active antibody designed to block the V-domain Ig
suppressor of T cell activation (VISTA) checkpoint selectively
within the low pH tumor microenvironment, where VISTA acts as a
suppressor of T cells by binding the receptor PSGL-1. The company
is also developing SNS-102, a conditional binding monoclonal
antibody targeting V-Set and Immunoglobulin Domain Containing 4
(VSIG-4), as well as SNS-103, also a conditionally active
monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more
information, please visit www.senseibio.com, and follow the company
on Twitter @SenseiBio and LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsAny statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may
be identified by words and phrases such as “believe”, “designed
to,” “expect”, “may”, “plan”, “potential”, “will”, and similar
expressions, and are based on Sensei’s current beliefs and
expectations. These forward-looking statements include expectations
regarding the development and potential therapeutic benefits of
Sensei’s product candidates, as well as the timing of Sensei’s
Phase 1/2 clinical trial of SNS-101, including reporting of data
therefrom. These statements involve risks and uncertainties that
could cause actual results to differ materially from those
reflected in such statements. Risks and uncertainties that may
cause actual results to differ materially include uncertainties
inherent in the development of therapeutic product candidates, such
as the risk that any one or more of Sensei’s product candidates
will not be successfully developed or commercialized; the risk of
delay or cessation of any planned clinical trials of Sensei’s
product candidates; the risk that prior results, such as signals of
safety, activity or durability of effect, observed from preclinical
trials, will not be replicated or will not continue in ongoing or
future studies or clinical trials involving Sensei’s product
candidates; the risk that Sensei’s product candidates or procedures
in connection with the administration thereof will not have the
safety or efficacy profile that we anticipate; risks associated
with Sensei’s dependence on third-party suppliers and
manufacturers, including sole source suppliers, over which we may
not always have full control; risks regarding the accuracy of our
estimates of expenses, capital requirements and needs for
additional financing; and other risks and uncertainties that are
described in Sensei’s Quarterly Report on Form 10-Q filed with the
U.S. Securities and Exchange Commission (SEC) on or about August 3,
2023 and Sensei’s other Periodic Reports filed with the SEC. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Sensei as of the
date of this release, and Sensei assumes no obligation to, and does
not intend to, update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Contact:Michael
BiegaSenior Director, Investor RelationsSensei
Biotherapeuticsmbiega@senseibio.com
Media Contact:Chris RaileyTen
Bridge Communicationschris@tenbridgecommunications.com
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024